CIK 0001706431
- Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812730369
- Phone
- +1 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-08-09 | Virgin Herbert EVP, Research & CSO | Option exercise | +70,177 | $1.53 | $107K | 254,584 |
| 2022-08-09 | Virgin Herbert EVP, Research & CSO | Option exercise | +7,916 | $10.40 | $82K | 262,500 |
| 2022-08-09 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −70,177 | 140,328 | ||
| 2022-08-09 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −7,916 | 125,416 | ||
| 2022-03-10 | Virgin Herbert EVP, Research & CSO | Option exercise | +9,000 | $1.53 | $14K | 184,407 |
| 2022-03-10 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −9,000 | 210,505 | ||
| 2022-02-22 | Virgin Herbert EVP, Research & CSO | Grant or award | +70,000 | 175,407 | ||
| 2022-02-22 | Virgin Herbert EVP, Research & CSO | Option exercise | +1,375 | $1.53 | $2K | 176,782 |
| 2022-02-22 | Virgin Herbert EVP, Research & CSO | Sale | −1,375 | $30.00 | $41K | 175,407 |
| 2022-02-22 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −1,375 | 219,505 | ||
| 2022-02-22 | Virgin Herbert EVP, Research & CSO | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2022-02-17 | Virgin Herbert EVP, Research & CSO | Sale | −2,293 | $31.93 | $73K | 105,407 |
| 2022-02-08 | Virgin Herbert EVP, Research & CSO | Option exercise | +1,375 | $1.53 | $2K | 109,075 |
| 2022-02-08 | Virgin Herbert EVP, Research & CSO | Sale | −1,375 | $33.94 | $47K | 107,700 |
| 2022-02-08 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −1,375 | 220,880 | ||
| 2022-01-25 | Virgin Herbert EVP, Research & CSO | Option exercise | +1,375 | $1.53 | $2K | 109,075 |
| 2022-01-25 | Virgin Herbert EVP, Research & CSO | Sale | −1,375 | $32.46 | $45K | 107,700 |
| 2022-01-25 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −1,375 | 222,255 | ||
| 2022-01-11 | Virgin Herbert EVP, Research & CSO | Option exercise | +1,375 | $1.53 | $2K | 109,075 |
| 2022-01-11 | Virgin Herbert EVP, Research & CSO | Sale | −1,375 | $35.10 | $48K | 107,700 |
Page 1 of 10 · 198 trades